New Migraine Drugs Stop Pain Before It Starts
A new class of drugs that blocks calcitonin gene-related peptide (CGRP)—a molecule in the body that spikes during a migraine attack—is being tested in clinical trials. The goal of this new medication—which is administered via an injection once a month—is to prevent migraines and migraine symptoms even before they start.
Testing results for the drugs are expected later in 2017 or in early 2018, and if approved by the U.S. Food Administration (FDA), the medicine could become available in 2018. So far, a large number of patients take the new drugs—but not all—have experienced a reduction in the frequency and intensity of migraine headaches.
If approved, this new migraine treatment could be life-changing for the more than 35 million people in the U.S. who suffer from migraines.
Image Credit: Thinkstock